Tag: FDA

FDA Approves Ketamine-Derived Antidepressant

Benjamin Olsen | @benpleasestop

The FDA just approved a new antidepressant, the first of its kind. Unlike other antidepressants, this one is a nasal spray. Esketamine, under the brand name Spravato, is developed by Johnson & Johnson and has been in testing for the past 2 years. The drug has seen remarkable success. This success is interesting because the drug is closely tied to the club drug “Special K.” Related to MDMA, Special K is known as Ecstasy. This marks the first major breakthrough in the treatment of depression since the 1980s.

Continue reading “FDA Approves Ketamine-Derived Antidepressant”

Advertisements

Xanax Makes Doctors Rich and People More Anxious

Cassandra Twining | United States

Doctors in the United States write 50 million Xanax prescriptions per year. That’s over one prescription per second. You can buy 30 Xanax pills at your local pharmacy for on average $100. That amounts to five billion dollars being spent on Xanax every single year. But what exactly is Xanax and how does it work?

Xanax, also commonly known by its cheaper off-brand counterpart Alprazolam, is a Benzodiazepine. It is commonly used to treat general anxiety disorder, panic disorders, and insomnia. Benzodiazepines are a specific category of drug that works in specific receptors in your brain. The Benzodiazepines, in this instance, Xanax, attaches to the gamma-aminobutyric acid-A (GABA-A) receptors in your brain and diminish sensitivity to stimulation, which in turn produces the calming effect so many people love. Xanax is listed by the Drug Enforcement Agency as a schedule 4 drug. This essentially means that it is the second least likely to lead to addiction and it is very safe to take. At least according to their classification that is… So let’s look a little more into what exactly Xanax does to your brain along with the long term effects.

Treating anxiety disorders can be very difficult for some people because of the vast amount of kinds of ways anxiety can present itself. While Xanax is not the only option for treating anxiety medically, it is certainly the most commonly prescribed and most well-known option. There are 3 fundamental problems with Xanax and its long term effects on the brain.

Treating Symptoms, not Problems

The first problem being that Xanax doesn’t stop one’s anxiety, it merely numbs it. When the medication goes into the receptors in your brain and dims the sensation in the brain it effectively reduces the release of the chemicals in your brain that causes anxiety. However, the issue arises from the fact that a reduction of the release of the chemicals does not mean they go away, it just builds up.

This is why when people try to quit taking Xanax or the dosage they took wears off the anxiety feelings not only come back but comes back more forcefully. It’s essentially like sweeping dirt under a rug; it’s still there and it’s still going to affect you eventually. The problem is just continuing to build up and get worse.

This problem is enhanced by the second problem faced with Xanax: it has an incredibly short half-life. Meaning that the amount of time it takes for the drug to completely leave your system is really quick. Which makes people want to take more of the medication even when they’re not scheduled to because of the adverse effects that come when it wears off.

Xanax Addiction and Overdose

Both problems, in turn, contribute to the third and final problem that Xanax is highly addictive. Because of the short half-life, the increase in anxiety when it wears off, and the effectiveness of the drug, people quickly become both physically and emotionally dependant on Xanax as a treatment for their anxiety.

It is also very possible to overdose on Xanax, especially taken with other opioids or alcohol. In 2015 over 30,000 drug overdose deaths were the result of opioids mixed with benzos like Xanax. It is also important to note that these numbers of Xanax use are only those prescribed by doctors; Xanax is also a very commonly used recreational drug. Doctors and pharmaceutical companies are making billions of dollars from prescribing and encouraging the consumption of a drug that is continuing to increase the amounts of anxiety and addiction in our country.

Treating Anxiety

Nevertheless, anxiety is a very real and serious issue. So what can people do to change the current system for go to treatment options? A community health center in Louisville, Kentucky started to notice how the mass amounts of Xanax prescriptions for patients were not only dangerous but also a drain on their resources.

Because of the lack of education surrounding the long term effects of Xanax they were also spending an enormous amount of time just simply educating people about it. This is why they decided to switch to prescribing clonazepam a similar drug with less adverse long term effects. They are trying to completely wean their patients off of Xanax altogether. There are some people who do truly benefit from its effects. However, it is such a dangerous drug that the risk just doesn’t appear to continue to be worth it.

Non-prescription Treatments

Finally, there are a lot of ways to try and alleviate anxiety using natural methods of treatment. Exercising can release endorphins and be a cathartic experience that can help with anxious feelings. Meditation and relaxation exercises like slowly relaxing each muscle group and breathing techniques can also help. You can also try reading, writing, natural medical treatments, or anything you may feel will help.

It’s most important to remember that anxiety isn’t the same for everyone and what might work for you might not work for someone else. It takes hard work and bravery to evaluate your options and find the best course of treatment for you. It’s okay to not want to try modern medical solutions, and it’s okay to want to! What’s not okay is not having the full story of how these solutions actually affect you. Do your research and make sure you’re not just making the problem worse while trying to solve it.


71 Republic is the Third Voice in media. We pride ourselves on distinctively independent journalism and editorials. Every dollar you give helps us grow our mission of providing reliable coverage. Please consider donating to our Patreon.

Featured Image Source

National Parks Are Kicking Out Libertarians… For Cleaning Them Up

By Mason Mohon | @mohonofficial

The government shutdown has turned into the longest one in United States history. The consequences have included our TSA not being paid (scary!) and the National Parks losing funding. In addition, the FDA is shut down. So amidst the constant slew of overdoses on cheap EpiPens and terrorist attacks, some kind-hearted libertarians decided to step up to the plate and do their part for nature.

Continue reading “National Parks Are Kicking Out Libertarians… For Cleaning Them Up”

How the United States Can Increase Market Freedom

By Max Bibeau | United States

The American Dream, as outlined by the Founding Fathers in the Declaration of Independence, has long been the shining beacon of hope for citizens and foreigners alike, offering a chance to be successful on an even playing field. Unfortunately, that beacon has been dimming in recent decades, leading the World Economic Forum to bluntly mourn that the American Dream is broken.

As class mobility continues to fall and the economic gap between rich and poor only seems to expand, many Americans are starting to give up hope in American capitalism. This has led to mass calls for change among the general populace, with everyone desperately looking for solutions. Some, such as Vermont Senator and 2016 presidential candidate Bernie Sanders, propose that it is time to look towards “democratic socialism” in the United States. Others, such as Speaker of the House Paul Ryan, seem to be denying the problem completely, still claiming that “the circumstances of your birth do not determine the outcome of your life.”

As much as we might wish for Paul Ryan’s statement to be true, the facts stand against him. Since we are in grave need of a solution, and one does not appear to be coming anytime soon, we must ask how America can improve competition in modern capitalism. Luckily, it is not too late for capitalism to be saved and for America to recover, but the country needs to act fast. While there are many potential solutions, there are three primary ones which will specifically target major problems in the US economy. In order to address current problems in the economy, the United States should target inefficiencies in regulatory organizations like the FDA, foster blockchain development around the country, and crack down on state preference policies.

FDA Inefficiency

The problem of skyrocketing drug prices was first brought to the forefront of American politics in 2015 when the infamous Martin Shkreli increased prices on a lifesaving drug by over 4000%, from $18 a pill to $750 a pill, making the cost of treatment virtually impossible to cover. Unfortunately, this is not an isolated case, as the Center for American Progress describes how American pharmaceutical prices have “continued to skyrocket” in recent years, with manufacturers of Medicare-covered drugs raising prices 12% per year on average. Another study shockingly found that over the past 14 months, 20 different prescription drugs had their prices increased by 200% or more.

Price increases, especially of these unprecedented proportions, are a clear indicator of a lack of competition within the pharmaceutical industry, as confirmed by a Government Accountability Office study. To counteract price increases, the United States must directly tackle the sources of the problem: inefficiency and over-regulation, which leads to monopolistic markets. All of the prescription drugs that saw drastic price increases have one thing in common: they have little to no competition making the same substances. This is because of how unreasonably difficult and expensive it is to get a new drug approved for manufacturing by the FDA.

The Journal of Health quantifies just how expensive the process can be, totaling it at over $1.395 billion in out-of-pocket costs. That number skyrockets up to $2.870 billion when post-approval research and development costs are factored in. These astronomically high development costs make it extremely difficult for anybody looking to create a new drug to even get their business off the ground. High startup costs are one of the top reasons that new companies and drugs never find success, as it’s virtually impossible for new companies, even with perfect scientific viability, to raise nearly $3 billion in investments just to allow their drug to be widely sold.

Because of complex regulations and red tape encircling the pharmaceutical industry, it’s no surprise that the market is nearly devoid of competition. By removing excessive regulation on the industry and streamlining the FDA, new drugs could be approved faster and cheaper. This would dramatically lower startup costs for new businesses trying to develop drugs and would promote increased competition throughout the entire industry, making life-saving substances much more affordable.

Blockchain Growth and Development

The blockchain, developed and made popular by cryptocurrencies like Bitcoin, is currently a buzzword in American Congress. Politicians are scrambling to implement the budding technology into their cities and states, and have even formed the Congressional Blockchain Caucus to craft policy surrounding it. Luckily, the potential benefits of the blockchain, especially when it comes to increasing competition, cannot be overstated. To quickly summarize a complex technology, the blockchain is a completely digital, decentralized ledger of information, constantly being confirmed and updated by computers around the world. This has plenty of business applications.

Specifically, since the National Bureau of Economic Research contends that the blockchain removes almost all need for trust in a transaction, small businesses will no longer have to compete with larger businesses when it comes to reputability. Trust, especially when it comes to internet retail, is one of the largest problems that businesses face, preventing up to 30% of internet users from utilizing online retail at all.

However, as the blockchain expands and becomes more widely used, retailers, especially small, newer businesses, will be granted the same level of trust as established companies. The Pew Research Center has found that many consumers soon “expect to see improved technology emerge that will allow people to have confidence in the organizations and individuals with whom they interact online,” specifically through the blockchain. Once the blockchain and cryptocurrency have become mainstream, the issue of trust will be eliminated from the equation, promoting widespread competition in online retail by allowing small retailers with no reputation to provide legitimate competition to retail giants.

While many are afraid to buy from anywhere other than Amazon due to the threat of scams, the blockchain will almost completely mitigate that problem, giving startups a chance, and opening up the online retail industry to everyone. To promote this, the government should focus on effectively regulating and investing in blockchain companies. These regulations would allow them to thrive and innovate in the near future, while still protecting the safety of consumers.

Ending State Preference Policies

While it is commonly agreed upon by economists that international protectionism damages all parties involved, what is criminally under-discussed when it comes to increasing domestic competition is state-by-state protectionism, more commonly known as preference policies. These policies are outlined by the Mercatus Center, which describes that preference policies, often enacted by state or local governments, give a significant advantage to companies residing in-state when bidding on government projects.

When a state government wishes to have a project completed, whether it be building military bases or providing a government building with computers, they allow companies to bid on the project. In theory, this practice would reduce costs as much as possible, as competition drives prices lower. Unfortunately, as the Mercatus Center furthers, even if an out-of-state company bids with a significantly cheaper offer, the more expensive in-state company will still almost always get the job. Aside from drastically raising the costs of government projects on taxpayers, in-state preference policies are almost identical to international protectionist policies, and have almost identical impacts, especially when it comes to decreasing competition.

Essentially, these programs enable companies to raise their prices due to the lack of competition from other states. Similar to international protectionism, these policies are put in place with the goal of stimulating domestic growth. However, this growth often comes at the cost of cheap prices and quality services. While it may appear that this would only discourage competition when it comes to government services, that is not quite true. Because most of these state and local policies are very strict, they only give preference to companies that have a state/local business license, pay all state/local taxes, and hire only state/local employees.

Since these policies are so rigid, and only apply to exclusively state or local businesses, it often discourages companies, especially those which rely on government business to remain profitable, from expanding outside of state borders, given that they know this will likely cost them their government business. This has much more broad impacts, affecting competition around the entire nation.

An Increase in Market Freedom

The United States, viewed as a pioneer of capitalism around the world, has found itself entrapped by red tape and ineffective policies, all of which are hindering one of the key benefits of capitalism: competition. However, while the United States does have some dire problems, they can be addressed.

First, the country needs to crack down on inefficient and ineffective regulations, specifically in the pharmaceutical industry. Second, the US should encourage and foster blockchain development by establishing fair regulations that don’t stifle the technology. Finally, the unfair problem of in-state preference policies must be addressed. While hope may be in short supply for capitalists in the United States, some common sense changes to economic policy would allow the beacon of the American Dream to shine brightly once again. 


Get awesome merchandise. Help 71 Republic end the media oligarchy. Donate today to our Patreon, which you can find here. Thank you very much for your support!

Featured Image Source

Cannabis Cola: Coke Interested in CBD-infused Product

By Spencer Kellogg | @Spencer_Kellogg

The Marijuana boom is alive and well in the United States. Although many states contest the legality of marijuana, major American companies already have an eye on the future.

On Monday morning, Coke announced that it is in preliminary discussion with Aurora Cannabis Inc. According to a Bloomberg report, Coke has initiated talks with the Canada pot company over including the nonpsychoactive ingredient in its drink line in the future. The company refused to discuss the plan in depth. However, Coke spokesperson Kent Landers did confirm that the company is “closely watching” the sector.

Aurora’s stock price rocketed more than 25% following the news. Other leading companies such as Tilray also saw a significant uptick after the announcement. Aurora is one of the top cannabis companies in Canada with a market valuation of more than $8 billion. With Canada ready to legalize marijuana on Oct. 17, Canada companies have grown rapidly as consumers excitedly enter the nascent market.

The move marks a definitive shift in market interests for the soda giant who purchased Costa Coffee for $5 billion in early August. With concerns regarding the decline in soda consumption and an eye towards the regulation of soft drinks, Coke is hoping that cannabis-laced products could provide an entirely new market of consumers. It could also have an impact on the image of Coca-Cola as it attempts to gain traction with a younger generation.

The news is further validation that a major marijuana market is waiting to be tapped by consumers and speculators alike. Constellation Brands, the owner of Corona and Svedka vodka, recently invested $4 billion into the Canadian pot company Canopy Growth. Lagunitas already has a THC infused beer available for purchase at marijuana dispensaries in California.


Get awesome merchandise and help 71 Republic end the media oligarchy by donating to our Patreon, which you can find here. Thank you very much for your support!

Featured Image Source